tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

RYTM Stock Latest News

Rhythm Pharmaceuticals’ Setmelanotide Trial: A Potential Game-Changer in Obesity Treatment
Company AnnouncementsRhythm Pharmaceuticals’ Setmelanotide Trial: A Potential Game-Changer in Obesity Treatment
5d ago
RYTM
Rhythm Pharmaceuticals Advances Setmelanotide Study for Prader-Willi Syndrome
PremiumCompany Announcements
Rhythm Pharmaceuticals Advances Setmelanotide Study for Prader-Willi Syndrome
5d ago
RYTM
Rhythm Pharmaceuticals’ RM-718 Study: A Potential Game-Changer in Obesity Treatment
PremiumCompany Announcements
Rhythm Pharmaceuticals’ RM-718 Study: A Potential Game-Changer in Obesity Treatment
5d ago
RYTM
Rhythm Pharmaceuticals’ Setmelanotide Study: A Promising Step in Rare Obesity Treatment
PremiumCompany Announcements
Rhythm Pharmaceuticals’ Setmelanotide Study: A Promising Step in Rare Obesity Treatment
5d ago
RYTM
Rhythm Pharmaceuticals’ New Study on Bivamelagon: A Potential Game-Changer for Hypothalamic Obesity
PremiumCompany Announcements
Rhythm Pharmaceuticals’ New Study on Bivamelagon: A Potential Game-Changer for Hypothalamic Obesity
5d ago
RYTM
Rhythm Pharmaceuticals price target raised to $128 from $122 at BofA
PremiumThe FlyRhythm Pharmaceuticals price target raised to $128 from $122 at BofA
11d ago
RYTM
Rhythm Pharmaceuticals price target lowered to $139 from $157 at Goldman Sachs
Premium
The Fly
Rhythm Pharmaceuticals price target lowered to $139 from $157 at Goldman Sachs
16d ago
RYTM
Rhythm Pharmaceuticals price target raised to $129 from $122 at Morgan Stanley
Premium
The Fly
Rhythm Pharmaceuticals price target raised to $129 from $122 at Morgan Stanley
17d ago
RYTM
Buy Rating for Rhythm Pharmaceuticals: Promising Setmelanotide Efficacy and Market Potential in Hypothalamic Obesity
PremiumRatings
Buy Rating for Rhythm Pharmaceuticals: Promising Setmelanotide Efficacy and Market Potential in Hypothalamic Obesity
1M ago
RYTM
Rhythm Pharmaceuticals price target raised to $110 from $100 at H.C. Wainwright
PremiumThe Fly
Rhythm Pharmaceuticals price target raised to $110 from $100 at H.C. Wainwright
1M ago
RYTM
Rhythm Pharmaceuticals price target raised to $142 from $135 at Citizens JMP
PremiumThe Fly
Rhythm Pharmaceuticals price target raised to $142 from $135 at Citizens JMP
1M ago
RYTM
Rhythm Pharmaceuticals: Strong Commercial Strategy and Promising Market Potential for aHO Treatment Justifies Buy Rating
PremiumRatings
Rhythm Pharmaceuticals: Strong Commercial Strategy and Promising Market Potential for aHO Treatment Justifies Buy Rating
1M ago
RYTM
Rhythm Pharmaceuticals price target raised to $122 from $109 at Morgan Stanley
PremiumThe FlyRhythm Pharmaceuticals price target raised to $122 from $109 at Morgan Stanley
1M ago
RYTM
Rhythm Pharmaceuticals: Buy Rating Backed by FDA Priority Review and Positive Phase 3 Results
Premium
Ratings
Rhythm Pharmaceuticals: Buy Rating Backed by FDA Priority Review and Positive Phase 3 Results
2M ago
RYTM
Rhythm Pharmaceuticals announces FDA acceptance of sNDA for setmelanotide
Premium
The Fly
Rhythm Pharmaceuticals announces FDA acceptance of sNDA for setmelanotide
2M ago
RYTM
Rhythm Pharmaceuticals Advances Genetic Obesity Treatment with Setmelanotide Study
PremiumCompany Announcements
Rhythm Pharmaceuticals Advances Genetic Obesity Treatment with Setmelanotide Study
3M ago
RYTM
Rhythm Pharmaceuticals’ RM-718 Study: A Potential Game-Changer in Obesity Treatment
PremiumCompany Announcements
Rhythm Pharmaceuticals’ RM-718 Study: A Potential Game-Changer in Obesity Treatment
3M ago
RYTM
Rhythm Pharmaceuticals Advances Genetic Obesity Treatment with Setmelanotide Study
PremiumCompany Announcements
Rhythm Pharmaceuticals Advances Genetic Obesity Treatment with Setmelanotide Study
3M ago
RYTM
Rhythm Pharmaceuticals’ RM-718 Study: A Potential Game-Changer in Obesity Treatment
PremiumCompany Announcements
Rhythm Pharmaceuticals’ RM-718 Study: A Potential Game-Changer in Obesity Treatment
3M ago
RYTM
3 Best Stocks to Buy Now, 8/8/2025, According to Top Analysts
PremiumMarket News3 Best Stocks to Buy Now, 8/8/2025, According to Top Analysts
3M ago
CI
WIX
Strong Q2 Performance and Strategic Investments Drive Buy Rating for Rhythm Pharmaceuticals
Premium
Ratings
Strong Q2 Performance and Strategic Investments Drive Buy Rating for Rhythm Pharmaceuticals
3M ago
RYTM
Rhythm Pharmaceuticals price target raised to $100 from $80 at H.C. Wainwright
Premium
The Fly
Rhythm Pharmaceuticals price target raised to $100 from $80 at H.C. Wainwright
3M ago
RYTM

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >